MedCity News June 23, 2024
Frank Vinluan

Ascidian Therapeutics’ technology edits RNA to treat inherited disorders. While the startup’s lead internal program is for the retinal disorder Stargardt disease, its new R&D alliance with Roche will focus on developing RNA-editing therapies for neurological indications.

Biotechnology research has brought patients therapies made by editing DNA. Roche aims be part of the next wave of genetic medicines with a focus on RNA. Its latest move in this strategy is a partnership with Ascidian Therapeutics, a startup with technology that edits RNA to address multiple mutations driving a disease.

According to terms of the alliance announced this past week, Roche is paying $42 million up front for rights to use Ascidian’s RNA exon-editing technology for certain neurological targets. Specific targets...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Partnerships, Pharma / Biotech, Trends
Related Articles:
Bariatric Surgeons Being Put Out of Work by GLP-1 Drugs
The CMS NHE 2023 Report: An Incomplete Picture at a Pivotal Time
Gene Therapy Shows Long-Term Vision Benefits in Rare Eye Disease
A Biologist Explains The ‘Weird’ Habits Of People Who Live To 100+ Years Old
U.S. Health Care Spending Reaches $4.9 Trillion

Share This Article